Filing Flows › Prelude Therapeutics (PRLD) › Q4 2024
Prelude Therapeutics (PRLD) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 10, 2025
Prelude Therapeutics (PRLD) reported revenue of $4.0M for the fourth quarter 2024 (Q4 2024) and +33% from the quarter before. Operating margin was -845.8%, net loss $28.7M (718.3% of revenue).
Prelude Therapeutics, Q4 2024: revenue $4.0M, operating margin -845.8%, net loss $28.7M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +33% | — |
| Operating profit | −$33.8M | — | — |
| Net earnings | −$28.7M | — | — |
| Operating cash flow | −$20.7M | — | — |
What changed
Revenue was $4.0M in Q4 2024, up 33% from the previous quarter.
Operating costs exceeded revenue by $33.8M, an operating margin of -845.8%. The quarter ended with a net loss of $28.7M, narrower than the previous quarter's $32.3M loss.
Operating cash flow was −$20.7M. Non-cash charges added back $489K of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items added $3.7M. Capital expenditures of $53K exceeded it, leaving free cash flow of −$20.8M.
Questions
What was Prelude Therapeutics' revenue in the fourth quarter 2024?
Prelude Therapeutics (PRLD) reported revenue of $4.0M for the fourth quarter 2024 (Q4 2024) and +33% from the quarter before.
Was Prelude Therapeutics profitable in the fourth quarter 2024?
Operating loss was $33.8M (-845.8% of revenue) and net loss $28.7M.